Loading
Estrella Immunopharma, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Xu Jiandong, was filed 29 Apr 2026.
Estrella Immunopharma, Inc.: what insiders have been doing
Estrella Immunopharma, Inc. belongs to the Health Care sector. Filings by its managers are published through SEC (Form 4). Between 25 October 2025 and 25 October 2026, 2 insiders published 5 filings.
Only purchases show up on the open market, 3 purchases in all worth €2,213, filed by 1 insider. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The buyers include 1 finance chief. The largest single trade was a purchase of €1,141 by Xu Jiandong, published on 29 April 2026.
Compared with its exchange (3,167 companies, median 24 filings), a count of 5 filings is below the norm. Over the whole record (from 2022), the tally stands at 4 purchases and no sales. For the fiscal year to 31 December 2025, the annual 10-K puts net income at -13.1 m USD.
The last insider purchase was made public on 29 April 2026, 179 days ago.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and EssilorLuxottica. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
7
Thresholds
n/a
Buy Volume
€286,576
4 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleJiandong Xu3 buys
Since the insiders bought
- -39.9%Entry US$1.64 · Close 23 Oct 2026 US$0.99
- +5.1%Entry US$9.98 · Close at T+365 US$10.49
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.99
Analyst consensus
1 analysts0.00/5
US$12.00Target US$12.00(+1118%)US$12.00
Income statement
EBITDA-US$13.1M
Net income-US$13.1M0.0% margin
Valuation
PER (forward)-3.1x
Beta0.93
Balance sheet & cash
Market capUS$42.8M
Free Cash Flow-US$1.8M
Profitability & ownership
ROA-251.9%
% insiders60.4%
% institutions11.1%
Last declaration on 26 August 2026
Declarations7 total
100,000 shares@ US$0.8150.38% mcap100.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001996255-26-000004:0
100,000 shares@ US$0.8150.38% mcap97.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001213900-26-093698:0
100 shares@ US$1.040.1% of flowCommon Stock, par value $0.0001 per shareSEC:0001213900-26-049602:0
Canonical exit: 10 Dec 2025 (T+90)
1,000 shares@ US$1.161.4% of flowCommon Stock, par value $0.0001 per shareSEC:0001213900-26-049602:1
Canonical exit: 21 Dec 2025 (T+90)
1,000 shares@ US$1.331.6% of flowCommon Stock, par value $0.0001 per shareSEC:0001213900-26-049602:2
Canonical exit: 5 Jan 2026 (T+90)
255,000 shares@ US$10.86100.0% of flowCommon Stock, par value $0.0001 per shareSEC:0000902664-23-005013:0
141,970 shares@ US$2.2167100.0% of flowCommon StockSEC:0001104659-22-035068:0
Canonical exit: 2 Jun 2022 (T+90)
7 of 7 declarations
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc. is a company focused on developing immunological therapies for various diseases. It is listed on the XNAS market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
